A research team has discovered a previously unknown mechanism that could explain why many patients with aggressive B-cell lymphoma do not respond to CAR-T cell therapy in the long term. The results of ...

After treatment with CAR-T cells—immune cells engineered to attack cancer—patients sometimes tell their doctors they feel like they have “brain fog,” or forgetfulness and difficulty concentrating. A ...

A case report from German hematologists suggests that patients with advanced multiple myeloma may still benefit from a second ...

Researchers from City of Hope have developed a new "plug-and-play" technology that adds engineered molecules to chimeric ...

A research team from University Hospital Cologne and the University of Cologne’s Faculty of Medicine, led by Professor Dr Dr Roland Ullrich, Senior Physician at the Clinic I of Internal Medicine, has ...

LEXINGTON, Mass. and SINGAPORE, May 12, 2025 /PRNewswire/ -- Elpis Biopharmaceuticals, a clinical-stage cell therapy company developing bispecific armored CAR-T therapies for solid tumors, today ...

CAR T cell therapy cleared a toddler's chemotherapy-resistant liver cancer in two outpatient infusions, with no toxicity and ...

Yan Leyfman, MD, reviewed how toxicity management in hematologic oncology is shifting to phenotype- and mechanism-informed intervention. Leyfman highlighted the following key domains when it comes to ...

Ku, MD, highlights emerging therapies in the treatment paradigm for patients with gastric and gastroesophageal junction cancers. In a recent interview with Targeted Oncology, Geoffrey Y. Ku, MD, ...